Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

NCT07299890 is registered in ClinicalTrials.gov with Anhui Provincial Cancer Hospital as lead sponsor.

NCT NCT07299890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07299890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer
Lead sponsor
Anhui Provincial Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 20, 2025
Completion date
November 1, 2027
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer